Evaluation of Concordance Between the Cobas® BRAF V600 Mutation Assay and the Methods Used in INCa Platforms for Detection of BRAF V600 Mutations in Melanoma in Real Life Setting
N/A
N/A
N/A
N/A
N/A
Not Enrolling
Both
Malignant Melanoma
Both
Malignant Melanoma
Trial Information
Evaluation of Concordance Between the Cobas® BRAF V600 Mutation Assay and the Methods Used in INCa Platforms for Detection of BRAF V600 Mutations in Melanoma in Real Life Setting
Inclusion Criteria:
No patients are enrolled. Use of tumor samples only.
- Histologically proven melanoma tumor sample
- Any type of tumor sample: biopsy or surgical specimen of primary tumor or metastasis
- Tumor samples must be fixed and paraffin-embedded.
Exclusion Criteria:
No patients are enrolled. Use of tumor samples only.
- Fixative unknown
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
BRAF mutation status of melanoma tumor samples according to cobas® 4800 BRAF V600 Mutation Test vs. INCa laboratories molecular genetics platform
Outcome Time Frame:
Approximately 6 months
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
France: Ministry of Health
Study ID:
ML28471
NCT ID:
NCT01744860
Start Date:
December 2012
Completion Date:
April 2013
Related Keywords:
- Malignant Melanoma
- Melanoma
Name | Location |
|---|
